<DOC>
	<DOCNO>NCT00481247</DOCNO>
	<brief_summary>The purpose clinical research study compare confirm complete cytogenetic response dasatinib imatinib within 12 month randomization patient newly diagnose chronic-phase Philadelphia positive chronic myeloid leukemia . The safety treatment also study .</brief_summary>
	<brief_title>A Phase III Study Dasatinib v Imatinib Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Key Male female , age 18 year old Chronic phase , Philadelphia Chromosomepositive chronic myeloid leukemia ( CML ) Eastern Cooperative Oncology Group Performance Status score 02 Key Pleural Effusion Uncontrolled cardiovascular disease Significant bleeding disorder unrelated CML Prior treatment interferon/imatinib/dasatinib/antiCML systemic treatment except anagrelide/hydroxyurea</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia</keyword>
</DOC>